Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?

Approximately 50% of all melanomas harbor an activating BRAF mutation. In patients suffering from an advanced melanoma with such a somatic alteration, combined targeted therapy with a BRAF and MEK inhibitor can be applied to significantly increase the survival probability. Nevertheless, resistance m...

Descripción completa

Detalles Bibliográficos
Autores principales: Schummer, Patrick, Schilling, Bastian, Gesierich, Anja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371660/
https://www.ncbi.nlm.nih.gov/pubmed/32124332
http://dx.doi.org/10.1007/s40257-020-00509-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371660/
https://www.ncbi.nlm.nih.gov/pubmed/32124332
http://dx.doi.org/10.1007/s40257-020-00509-z

Ejemplares similares